InforMedix Signs University of Pennsylvania as First Self-Insured Employer Customer; Penn is Largest Private Employer in Philadelphia, Second Largest in Pennsylvania
ROCKVILLE, Md. — Human Resources Department to Offer “Interactive Pillbox” to Deliver Comprehensive Program for Employees with Diabetes, High Blood Pressure and/or High Cholesterol
InforMedix Holdings, Inc. (OTCBB:IFMX) today announced plans to offer the Med-eMonitor System, developed and patented by InforMedix, to selected University of Pennsylvania (Penn) employees and retirees with chronic health care conditions known to cause high rates of stroke, heart disease, premature death, and reduced quality-of-life.
Penn, the home of the nation’s first medical school, the largest private employer in Philadelphia, and the second largest employer in the Commonwealth of Pennsylvania, will be using its Cardiovascular Disease Risk Factor Care (CDRF) Management Team to administer this first-in-the-nation employee benefit program. This comprehensive program is designed to significantly improve patient outcomes and reduce health care costs.
This effort was led by Jack Heuer, Ed.D., Penn’s Vice President for Human Resources and Leny Bader, Penn’s Executive Director of Human Resources. According to Dr. Heuer, “Wellness and Disease Management is at the forefront of what we do in Human Resources at Penn. InforMedix offers a unique opportunity to blend technology with the expertise of Penn’s medical professionals to enhance the care adherence and healthy lifestyles of our faculty and staff.”
In the first phase of the program announced today, 100 selected patients will receive The Med-eMonitor(TM) System, which includes an “interactive pillbox” device that goes home with the patient. This highly interactive device alerts the patient when it is time to take medications, instructs the patient how to adhere to all aspects of their particular plan of care, and delivers important educational information. The CDRF team will monitor patient data through a secure Internet site and alert patients and their healthcare professionals to early signs of poor compliance or declining health.
Penn’s CDRF Management Team previously conducted a program for Type II diabetics in Montana using InforMedix’s Med-eMonitor System, whereby mean medication adherence rates improved to over 92% compared to a baseline medication adherence rate of 40%, and Hemoglobin A1c (HbA1c) levels were reduced by an average of 18.5% in a 3 month period (p less than .002). Reductions in HbA1c, hypertension, and cholesterol are associated with improved lifespan and morbidity and a significant reduction in healthcare costs in the treatment of Diabetes patients.
Bonne Farberow, RN, CCRA, CCRP, Project Director, Division of Cardiology, the Hospital of the University of Pennsylvania, and team leader of the Cardiovascular Disease Risk Factor Care Management Group stated, “In the Montana Diabetes Program patients were successfully monitored remotely, which offered the increased capability of the healthcare professionals and patients to intervene with necessary medication or care plan changes on a daily or weekly basis, if needed. The Med-eMonitor System was well received by patients and the healthcare professionals participating in that Program. We look forward to the opportunity to improve health outcomes with our own faculty and staff here at the University of Pennsylvania.”
Dr. Bruce Kehr, Chairman and CEO of InforMedix commented “The University of Pennsylvania operates one of the most prestigious medical centers in the United States. For them to offer the Med-eMonitor as a patient benefit represents a significant milestone in our effort to roll-out this system nationwide. Major employers like Penn who self-insure are searching for ways to reduce health care costs without sacrificing the quality of care provided. What is exciting about the Med-eMonitor System is that by improving medication and care plan adherence, it not only improves patient outcomes but also reduces healthcare costs.”
Literature substantiates that reduced HbA1c levels of just 10% have been associated with a cost reduction of $10,800 per patient, and an increased life expectancy of one year. The annual combined drug and medical costs for the most compliant diabetes patients average $4,570, which is almost 50 percent below the $8,867 cost for the least compliant group. Proper medication adherence also reduces the risk of stroke by 31% to 51%, and the risk of heart attacks and death by 24%, in diabetic hypertensive patients with elevated cholesterol.
Dr. Kehr said that the Med-eMonitor System “Consistently delivers medication and care plan adherence rates of over 90% in patients suffering from congestive heart failure, diabetes, and/or schizophrenia. We applaud the visionary innovation by Penn to be the first large employer to implement this program to enhance the benefit they offer to their employees, and believe that major employers around the country will be watching this exciting program.”
InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients’ medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in disease management and clinical drug trials programs. The Med-eMonitor System leverages InforMedix’s strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix’s patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB:IFMX), visit our website at www.informedix.com.
This report contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These forward-looking statements include “InforMedix offers a unique opportunity to blend technology with the expertise of Penn’s medical professional to enhance the care adherence and healthy lifestyles of our faculty and staff.” References made to the discussion of the risk factors are detailed in the Company’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning